Clinical trials: Contrast Media
Cardiovascular Diseases, Microvascular Complications
Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study
Microvascular dysfunction, particularly endothelial dysfunction, is increasingly recognized as a key mechanism underlying various cardiovascular diseases (CVD), including heart failure, ischemic heart disease, atherosclerosis…
- Trial name
- NCT07359768
- Where
- Sweden
- Volunteers
- 900 people
- Sponsor
- HJN Sverige AB/Neko Health
Oocyte Competence
Modulation Contrast Microscopy Imaging for Oocyte Quality Assessment
The present study aims to describe novel non-invasive parameters related to the competence of female reproductive cells (oocytes).
- Trial name
- NCT03683290
- Testing
- Image acquisition and analysis
- Where
- United Kingdom
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Center for Reproductive an Genetic Health
Magnetic Resonance Imaging
Contrast-enhanced MRI in Children 2 Months to <2 Years
The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age
- Trial name
- NCT00937391
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Where
- 13 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Bayer
Cataract
Evaluation of the EpiGlare Tester for the Measurement of Glare-Induced Changes in BSCVA in Subjects With and Without Cataracts
The EpiGlare Tester will identify visual disability resulting from the glare experienced by subjects with cataracts in the glare-induced change in best spectacle corrected visual acuity (BSCVA).
- Trial name
- NCT04739397
- Testing
- Glare Testing
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Epico, LLC
Contrast Enhanced Computed Tomography
Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans
The purpose of this study is to compare multidetector computed tomography (CT) image quality following peripheral venous high pressure injection of iodinated intravenous contrast media between a 20 gauge (GA) fenestrated…
- Trial name
- ARCTR05 (NCT01772550)
- Testing
- 20GA BD Nexiva Diffusics, 18GA Conventional Catheter
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- Quanti OBR (NCT05915728)
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine
- Where
- 85 sites in United States, Argentina and 14 more
- Volunteers
- 410 people
- Sponsor
- Bayer
Coronary Artery Disease
Dynamic Coronary Roadmap for Contrast Reduction
The Dynamic Coronary Roadmap is a commercially available product developed by Philips Medical Systems, a Philips Healthcare company.
- Trial name
- DCR4Contrast (NCT04085614)
- Testing
- Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap, Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 371 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Coronary Artery Disease
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.
- Trial name
- NCT00594698
- Testing
- PB127 for injectable suspension
- Where
- 34 sites in United States
- Volunteers
- 150 people
- Sponsor
- Point Biomedical
Hypothyroidism
Thyroid Function of Pediatric Subjects Following Isovue® Administration
This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the…
- Trial name
- NCT03779906
- Testing
- Isovue
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bracco Diagnostics, Inc
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
- Trial name
- NCT06338995
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 202 sites in United States, Argentina and 18 more
- Volunteers
- 510 people
- Sponsor
- Eli Lilly and Company
Healthy
Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers
To optimize both the Ioforminol concentration and dosage(s) for CECT of the abdomen. To evaluate the safety and tolerability of low concentration Ioforminol Injections. Study recruits healthy volunteers.
- Trial name
- NCT01672996
- Testing
- Ioforminol 160 mgI/mL, Ioforminol 200 mgI/mL, Iopamidol 300 mgI/mL
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Contrast-induced Nephropathy
Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
Randomized parallel group study comparing the renal safety of Captisol-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in patients with impaired renal function undergoing coronary angiography.
- Trial name
- NCT04627831
- Testing
- CE-Iohexol, Iohexol
- Sponsor
- Ligand Pharmaceuticals
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Renal Insufficiency
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial.
- Trial name
- RESCUE (NCT00650845)
- Testing
- Dotarem®-enhanced MRI, non-enhanced MRI
- Where
- 15 sites in Belgium, France and 2 more
- Volunteers
- 135 people
- Sponsor
- Guerbet
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595244
- Testing
- PB127 for injectable suspension
- Where
- 15 sites in United States
- Volunteers
- 456 people
- Sponsor
- Point Biomedical
Unspecified Adult Solid Tumor, Protocol Specific
Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors
RATIONALE: Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00091052
- Testing
- sargramostim, radiation therapy
- Where
- United States
- Sponsor
- Sirius Medicine
Contrast-induced Nephropathy, Chronic Kidney Diseases
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
Multi-center randomized trial to assess the safety and performance of low-frequency therapeutic ultrasound for maintaining renal function after contrast exposure.
- Trial name
- LOTUS (NCT04877847)
- Testing
- Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sonogenix
Contrast-Enhanced Magnetic Resonance Imaging Detection
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study. The primary objectives are: To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single…
- Trial name
- NCT06657560
- Testing
- HRS-9231
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Rheumatoid Arthritis
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis
The purpose of this study is to assess whether DCE-MRI can detect changes of active disease in rheumatoid arthritis (RA) patients after 4, 8 and 12 weeks of etanercept.
- Trial name
- NCT00361634
- Testing
- Etanercept
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Amgen